Monographie - Piperacillin sodium / tazobactam

Last update :
19/11/2024

Piperacillin sodium / tazobactam

Chemical structure

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bagotaz	Argentina
Betampil	Ecuador
Bioval	Chile
Petezam	Argentina
Piperac	Germany
Piperacillin tazobactam	Belgium, Canada, Germany
Piperazam	Brazil
Pipetazo	Chile
Pipitaz	Austria
Pixamol	Colombia
Tazobac	Ecuador, Italy, Portugal, Switzerland
Tazocel	Spain
Tazocilline	France
Tazocin	Argentina, Australia, Brazil, Colombia, Croatia, Denmark, Egypt, Finland, Great Britain, Greece, Hungary, Italy, Luxembourg, Mexico, Netherlands, New Zealand, North Ireland, Norway, Peru, Poland, Republic of South Africa, Sweden, Turkey, United Arab Emirates
Tazonam	Austria, Chile
Tazopip	Australia
Tazpen	Colombia, Mexico
Tazrobida	Colombia
Tigux	Chile
Tratac	Chile
Trital	Ecuador
Zosyn	Japan, United States of America

References : Piperacillin sodium / tazobactam

	Type	Publication
16	Journal	Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA. Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1554-1556.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
235	Journal	Choi JS, Burm JP, Jhee SS, Chin A, Ulrich RW, Gill MA. Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 2273-2276.
251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
274	Journal	Moon YSK, Chung KC, Chin A, Gill MA. Stability of piperacillin sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride minibags. Am J Health-Syst Pharm 1995 ; 52: 999-1001.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1508	Journal	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Journal	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1674	Journal	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Journal	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1946	Journal	Hecq JD, Berlage V, Vanbeckbergen D, Jamart J, Galanti L. Effects of freezing, long-term storage, and microwave thawing on the stability of piperacillin plus tazobactam in 5% dextrose for infusion. Can J Hosp Pharm 2004 ; 57, 5: 276-282.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Journal	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2026	Journal	Rigge D, Jones MF. Shelf lives of aseptically prepared medicines - stability of piperacillin/tazobactam in PVC and non-PVC bags. J Pharm Biomed Anal 2005 ; 39: 339-343.
2042	Journal	Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM. Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2087	Journal	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Journal	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	Journal	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Journal	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Journal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2345	Journal	Donnelly R.F. Stability of aseptically prepared Tazocin solutions in polyvinyl chloride bags. Can J Hosp Pharm 2009 ; 62, 3: 226-231.
2451	Journal	Park TW, Le-Bui LP, Chung KC, Rho JP, Gill MA. Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions Am J Health-Syst Pharm 1995 ; 52: 2022 - 2024.
2475	Journal	Wade J, Cooper M, Ragan R. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam Hosp Pharm 2015 ; 50: 376-379.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3254	Journal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Manufacturer	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3365	Journal	Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. Y-Site Compatibility of Vancomycin and Piperacillin/Tazobactam at Commonly Utilized Pediatric Concentrations. Hosp Pharm 2013 ; 1: 44-47
3385	Journal	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3421	Journal	Leung E, Venkatesan N, Ly S.C, Scheetz M.H. Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions. Am J Health-Syst Pharm 2013 ;70:1163-1166.
3428	Journal	Nichols K.R, DeMarco M.W, Vertin M.D, Knoderer C.A. Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations. Hosp Pharm 2013 ; 48, 1: 44-47.
3520	Manufacturer	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3529	Manufacturer	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3549	Manufacturer	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	Journal	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3586	Manufacturer	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3595	Manufacturer	Aciclovir - Summary of Product Characteristics Hospira 2009
3643	Manufacturer	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3841	Journal	Nicholas O?Donnell J, Venkatesan N, Manek M, Rhodes N.J, Scheetz M.H. Visual and absorbance analyses of admixtures containing vancomycin and piperacillin–tazobactam at commonly used concentrations. Am J Health-Syst Pharm 2016 ; 73:241-246
3948	Journal	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3960	Journal	Kufel W.D, Miller C.D, Johnson P.R, Reid K., Zahra J.J, Seabury R.W. Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story? Hosp Pharm 2017 ;52,2:132-137.
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3984	Journal	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
3997	Journal	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4148	Journal	Huvelle S, Godet M, Galanti L, Closset M, Bihin B, Jamart J, Hecq J.D. Long-Term Stability Comparison between an Original and a Generic Version of Piperacillin/Tazobactam in Dextrose 5% Infusion Polyolefin Bags at 5+/-3°C after Microwave Freeze-Thaw Treatment. Pharmaceutical Technology in Hospital Pharmacy 2018
4180	Journal	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4254	Journal	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4326	Journal	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.
4354	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019
4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4470	Journal	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4512	Journal	Jamieson C,Ozolina L,Seaton RA, Gilchrist M, Hills T, Drummond F, Wilkinson AS. Assessment of the stability of citrate- buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements EJHP 2020 2020;0:1-5.
4521	Journal	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4538	Journal	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4569	Journal	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4620	Quality control laboratory	SimmsD, Roberts J, Rigge D. Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Sodium Chloride 0.9% w/v in 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4621	Quality control laboratory	Simms D, Roberts J, Rigge D. Stability Study for Piperacillin/Tazobactam 56.9 mg/mL in Glucose 5.0% w/v in 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4634	Journal	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4655	Journal	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4758	Journal	Schmidt J.P, Steppe M. Stability Study and Simultaneous Determination of Norepinephrine, Moxifloxacin, and Piperacillin + Tazobactam Mixtures Applied in Intensive Care Medicine . Curr Pharm Anal 2023 ; 19, 4: 307-316.
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	Journal	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4842	Journal	Souha H Y, Alka G, Yunmei S, Nicole E W, Sanjay G. Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther 2024 Drug Design, Development

Mentions Légales